Tara Ryan Joins AAM as Vice President, State Government Affairs | Association for Accessible Medicines
AAM All Access Podcast - Dan Leonard speaks to AAM's Lisa Parks and Monét Stanford

Tara Ryan Joins AAM as Vice President, State Government Affairs

WASHINGTON DC (May 14, 2018) – Tara Ryan joins the Association for Accessible Medicines’ (AAM) State Government Affairs team as Vice President, State Government Affairs, effective today. She reports to Chris Bowlin, Senior Vice President, Government Affairs.

"Tara joins the generics industry at a time when the challenges to patient access from misguided legislation in the states are growing greater," says Bowlin. "Her unique skill set, reputation among state lawmakers and track record of success will serve the generics and biosimilars industry well as we educate legislators about the crucial part generic and biosimilar medicines play in driving down the cost of pharmaceuticals."

Throughout her career, Ryan advocated on a wide range of high-profile state public policy issues affecting patient access to prescription medicines including Medicaid and insurance coverage, responsible drug disposal, prescription drug abuse and the important role of pharmaceuticals in addressing the needs of patients. She also led state outreach to attorneys general, state physician groups and other state opinion leaders.

“More and more prescription drug policy is being considered in states. My priority is to create broader support across the states for a pro-generic and biosimilar legislative policy agenda that includes helping state policymakers better understand how affordable, FDA-approved generic and biosimilar medicines benefit patients’ health and their wallets, as well as state programs,” adds Ryan.

Prior to joining AAM, Ryan was Vice President, State Policy, at PhRMA, the trade association for the brand-name pharmaceutical industry.

View Bio

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.